Affordable Insulin!
Pharmaceutical company Eli Lilly updates their 2020 Affordable Insulin Program
Yesterday U.S. pharmaceutical manufacturer, Eli Lilly, made a statement declaring patients will pay a maximum of $35 out-of-pocket for their monthly insulin prescription. This announcement echoes a previous 2020 press release from the company when they introduced the Lilly Insulin Value Program allowing anyone with commercial insurance and those without insurance to purchase most Lilly insulins for a co-pay of $35 or less. The program was designed in response to the crisis caused by Covid-19 immediately slashing the cost of most Eli Lilly insulin products.
The 2023 news release repeats most of the same statements made in 2020, while additionally pledging to cut the price of their non-branded Insulin Lispro Injection to $25 a vial effective May 1st, 2023. This will be the lowest priced mealtime insulin available and cost less than a vial of Eli Lilly’s brand-named Humalog insulin in 1999.
Eli Lilly is the manufacturer behind commonly prescribed medications such as Prozac, Cymbalta, Cialis and many more. The company is also responsible for a majority of the global insulin market alongside Novo Nordisk and Sanofi. These three companies together control over 90% of the global market by value. Visit the Eli Lilly Website for more information on the company’s affordable insulin program and to view their long list of pharmaceutical drugs they offer.
Download official news releases from Eli Lilly below!
April 7th, 2020
March 1st, 2023
-The Real McCoy